Skip to content
value.today

4D Molecular Therapeutics, Inc.

FDMT
$637 Mmarket cap on Aug 1, 2026-26.1% since Jan 2024
Compare
World rank
#11,522
Revenue
$85 M
For year ending December-2025
Net income
$-140 M
-164.4% margin
SEC filing
Employees
78
As on September-2020
value.today research

4D Molecular Therapeutics, Inc. in brief

4D Molecular Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Emeryville, California, USA. Its market value was $637 M on 1 August 2026, which makes it the 11,522nd largest listed company in the world and the 2,378th largest in the USA on this site. In the year to December 2025 it had sales of $85 M and a net loss of $140 M. It employs about 78 people and David Kirn is its chief executive. Its largest product and service lines by sales in 2025 were Collaboration and License Revenue (100%). By market, the largest shares of its 2025 sales came from Japan (100%) and USA (under 1%). Its shares trade under the symbol FDMT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics is an Innovative Gene Therapy company designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions. The company annual revenue is 6.99 million USD and 78 employees as on 2019. The headquarters is in USA.

4D Molecular Therapeutics, Inc. timeline

3 events, 2015–2025
  1. 2015
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. 🔔
    Initial public offering on Nasdaq as FDMT
    Final prospectus filed with the SEC on 14 December 2020; shares registered for exchange trading on 8 December 2020.
  5. 2025
  6. 💰
    Record revenue of $85 million
    FY2025, the highest of the 6 years on record.

Events of 4D Molecular Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$296 M$593 M$889 M$1.2 B202120222023202420252026

World rank over time

▼ down 3,706 places since 2021
2021-01-01: #7586#7,58620212022-01-07: #12298#12,29820222022-12-25: #10358#10,35820222023-07-30: #10150#10,15020232024-01-05: #9372#9,37220242026-03-08: #7100#7,10020262026-08-01: #11292#11,2922026

Rank in USA: #2,077 (Jan 2021) · #3,049 (Jan 2022) · #2,305 (Dec 2022) · #2,326 (Jul 2023) · #2,135 (Jan 2024) · #1,244 (Mar 2026) · #2,379 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
6.6×
Price / book
1.3×
Free cash flow yield
-17.2%
Net margin (TTM)
-208.6%
Operating margin
-187.2%
Return on equity
-39.6%
Liabilities / assets
10.8%
Net debt
$-60M
Revenue growth
+212925.0%
R&D / revenue
229.7%
Revenue per employee
$1.1 M
Profit per employee
$-1.8 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue $7M, net income $-49M$7MFY19Fiscal year ending Dec 2020: revenue $14M, net income $-57M$14MFY20Fiscal year ending Dec 2021: revenue $18M, net income $-71M$18MFY21Fiscal year ending Dec 2022: revenue —, net income $-107M—FY22Fiscal year ending Dec 2023: revenue $21M, net income $-101M$21MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-161M$0MFY24Fiscal year ending Dec 2025: revenue $85M, net income $-140M$85MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$85M+212925.0%$-160M$-140M-164.4%
Dec 2024$0M-99.8%$-188M$-161M-402175.0%
Dec 2023$21M—$-113M$-101M-486.7%
Dec 2022——$-110M$-107M—
Dec 2021$18M+32.5%$-71M$-71M-395.3%
Dec 2020$14M+94.7%$-57M$-57M-416.5%
Dec 2019$7M—$-51M$-49M-705.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-109M$1M$-110M$-2.42—
Dec 2024$-135M$4M$-138M$-2.98—
Dec 2023$-76M$3M$-79M$-2.58—
Dec 2022$-87M$12M$-98M$-3.32—
Dec 2021$-69M$9M$-78M$-2.57—
Dec 2020$-51M$1M$-52M$-8.82—
Dec 2019$-37M$3M$-40M$-9.59—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$96M
Net income, trailing 12 months
$-200M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-50M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-48M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-55M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-57M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $85M, net income $19M$85MDec ’25Three months to Mar 2026: revenue $3M, net income $-69M$3MMar ’26Three months to Jun 2026: revenue $4M, net income $-73M$4MJun ’26Three months to Sep 2026: revenue $4M, net income $-78M$4MSep ’26

Latest quarter to Sep 2026: revenue $4M (+4500.0% on a year earlier), net income $-78M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of 4D Molecular Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$85 M
Operating income
$-160 M
Net income
$-140 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$567 M
Total liabilities
$61 M
Total equity
$506 M

As of December-2025

Top 100 institutional investors in 4D Molecular Therapeutics, Inc.#

As of Sep 30, 2026
167 institutions held 58.0 M shares (about 91.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 54.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in 4D Molecular Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.5,734,905—9.08%$82 MNov 16, 2026
2Ra Capital Management, L.P.5,049,7790 (0.00%)8.00%$72 MNov 16, 2026
3BlackRock, Inc.4,724,904+178,845 (+3.93%)7.48%$68 MNov 13, 2026
4Goldman Sachs Group Inc3,930,407-328,261 (-7.71%)6.23%$56 MNov 16, 2026
5Novo Holdings A/s3,000,000-249,178 (-7.67%)4.75%$43 MNov 16, 2026
6BVF Inc/il2,879,2890 (0.00%)4.56%$41 MNov 16, 2026
7State Street Corp2,469,425-441,684 (-15.17%)3.91%$35 MNov 12, 2026
8Adage Capital Partners GP, L.L.C.2,289,203+40,000 (+1.78%)3.63%$33 MNov 16, 2026
9T. Rowe Price Investment Management, Inc.2,266,034-245,853 (-9.79%)3.59%$32 MNov 16, 2026
10Trails Edge Capital Partners, LP2,227,9170 (0.00%)3.53%$32 MNov 16, 2026
11Vanguard Capital Management LLC2,140,758+41,703 (+1.99%)3.39%$31 MNov 13, 2026
12Armistice Capital, LLC1,950,000-50,000 (-2.50%)3.09%$28 MNov 16, 2026
13Bank Of America Corp /de/1,534,999+414,325 (+36.97%)2.43%$22 MNov 16, 2026
14Geode Capital Management, LLC1,184,271+55,805 (+4.95%)1.88%$17 MNov 6, 2026
15Morgan Stanley1,090,649+587,629 (+116.82%)1.73%$16 MNov 13, 2026
16Evergreen Quality Fund GP, Ltd.951,4740 (0.00%)1.51%$14 MNov 16, 2026
17Dimensional Fund Advisors LP787,000+56,143 (+7.68%)1.25%$11 MNov 4, 2026
18Parkman Healthcare Partners LLC772,177-176,007 (-18.56%)1.22%$11 MNov 16, 2026
19Catalio Capital Management, LP684,753+213,499 (+45.30%)1.08%$10 MNov 16, 2026
20Vanguard Portfolio Management LLC578,930-973 (-0.17%)0.92%$8 MNov 13, 2026
21Deutsche Bank AG\546,088-164,854 (-23.19%)0.86%$8 MNov 6, 2026
22Northern Trust Corp540,163-22,766 (-4.04%)0.86%$8 MNov 16, 2026
23Acuta Capital Partners, LLC535,109+27,308 (+5.38%)0.85%$8 MNov 16, 2026
24Charles Schwab Investment Management Inc438,712+99,437 (+29.31%)0.69%$6 MNov 16, 2026
25Diadema Partners LP421,107-150,000 (-26.26%)0.67%$6 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in 4D Molecular Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Renaissance Technologies LLC411,786-202,787 (-33.00%)0.65%$6 MNov 12, 2026
27Jpmorgan Chase & Co393,029-9,108 (-2.26%)0.62%$6 MNov 12, 2026
28Nuveen, LLC390,869-112,202 (-22.30%)0.62%$6 MNov 10, 2026
29Opaleye Management Inc.334,4370 (0.00%)0.53%$5 MNov 16, 2026
30FMR LLC311,944+183,628 (+143.11%)0.49%$4 MNov 10, 2026
31HRT Financial LP305,926New0.48%$4 MNov 13, 2026
32Vanguard Fiduciary Trust Co300,719+24,481 (+8.86%)0.48%$4 MNov 13, 2026
33Burkehill Global Management, LP275,0000 (0.00%)0.44%$4 MNov 16, 2026
34Invesco Ltd.260,116+109,734 (+72.97%)0.41%$4 MNov 12, 2026
35Raymond James Financial Inc241,860-489 (-0.20%)0.38%$3 MNov 12, 2026
36Brevan Howard Capital Management LP203,800+26,950 (+15.24%)0.32%$3 MNov 16, 2026
37ArrowMark Colorado Holdings LLC202,8640 (0.00%)0.32%$3 MNov 16, 2026
38Woodline Partners LP200,0010 (0.00%)0.32%$3 MNov 16, 2026
39Voya Investment Management LLC191,868+51,668 (+36.85%)0.30%$3 MNov 10, 2026
40Barclays PLC179,867+156,042 (+654.95%)0.28%$3 MNov 6, 2026
41Propel Bio Management, LLC179,154-73,500 (-29.09%)0.28%$3 MNov 13, 2026
42Federated Hermes, Inc.176,677-45,739 (-20.56%)0.28%$3 MNov 12, 2026
43Schonfeld Strategic Advisors LLC175,180-232,290 (-57.01%)0.28%$3 MNov 16, 2026
44Jane Street Group, LLC171,009New0.27%$2 MNov 12, 2026
45Wellington Management Group LLP162,802+34,338 (+26.73%)0.26%$2 MNov 16, 2026
46Citadel Advisors LLC154,311-533,286 (-77.56%)0.24%$2 MNov 16, 2026
47Bank of New York Mellon Corp152,578+241 (+0.16%)0.24%$2 MNov 5, 2026
48Greenland Capital Management LP151,762+79,505 (+110.03%)0.24%$2 MNov 16, 2026
49Ikarian Capital, LLC150,037New0.24%$2 MNov 16, 2026
50Trexquant Investment LP148,305New0.23%$2 MNov 16, 2026
51Perigon Wealth Management, LLC146,1850 (0.00%)0.23%$2 MOct 22, 2026
52Millennium Management LLC136,373New0.22%$2 MNov 16, 2026
53American Century Companies Inc127,965+13,965 (+12.25%)0.20%$2 MNov 12, 2026
54Susquehanna International Group, LLP122,351+110,190 (+906.09%)0.19%$2 MNov 16, 2026
55UBS Group AG118,127-138,546 (-53.98%)0.19%$2 MNov 10, 2026
56Susquehanna Portfolio Strategies, LLC110,985+4,050 (+3.79%)0.18%$2 MNov 16, 2026
57Persistent Asset Partners Ltd106,954-38,631 (-26.54%)0.17%$2 MNov 13, 2026
58Hussman Strategic Advisors, Inc.105,000New0.17%$2 MNov 2, 2026
59Two Sigma Investments, LP93,432+23,951 (+34.47%)0.15%$1 MNov 16, 2026
60Privium Fund Management B.V.90,1100 (0.00%)0.14%$1 MNov 3, 2026
61State Of Wisconsin Investment Board83,762+27,510 (+48.90%)0.13%$1 MNov 16, 2026
62Assenagon Asset Management S.A.83,333-83,333 (-50.00%)0.13%$1 MOct 15, 2026
63Acadian Asset Management LLC82,927-80,618 (-49.29%)0.13%$1 MNov 9, 2026
64Citigroup Inc75,204+5,992 (+8.66%)0.12%$1 MNov 4, 2026
65Alps Advisors Inc73,175+20,119 (+37.92%)0.12%$1 MNov 3, 2026
66DekaBank Deutsche Girozentrale61,000+31,000 (+103.33%)0.10%$1 MOct 27, 2026
67TD Asset Management Inc60,758+9,276 (+18.02%)0.10%$1 MNov 13, 2026
68Quantinno Capital Management LP60,506+2,424 (+4.17%)0.10%$1 MNov 13, 2026
69Rhumbline Advisers58,948-690 (-1.16%)0.09%$1 MNov 10, 2026
70Fisher Asset Management, LLC58,546-7,205 (-10.96%)0.09%$1 MNov 6, 2026
71Aquatic Capital Management LLC56,884New0.09%$1 MNov 16, 2026
72Informed Momentum Co LLC55,873New0.09%$1 MNov 16, 2026
73Price T Rowe Associates Inc /MD/54,8690 (0.00%)0.09%$1 MNov 16, 2026
74AQR Capital Management LLC53,672+3,391 (+6.74%)0.09%$1 MNov 16, 2026
75BNP Paribas Financial Markets53,624+45,428 (+554.27%)0.08%$1 MNov 12, 2026
76Rafferty Asset Management, LLC50,998+6,284 (+14.05%)0.08%$1 MNov 13, 2026
77Affinity Asset Advisors, LLC50,000New0.08%$1 MNov 13, 2026
78SEI Investments Co49,913+33,249 (+199.53%)0.08%$1 MNov 10, 2026
79Qube Research & Technologies Ltd49,520New0.08%$1 MNov 13, 2026
80Panagora Asset Management Inc46,9820 (0.00%)0.07%$1 MNov 12, 2026
81D. E. Shaw & Co., Inc.44,654+300 (+0.68%)0.07%$1 MNov 16, 2026
82Alliancebernstein L.P.44,100-11,640 (-20.88%)0.07%$1 MNov 16, 2026
83Boothbay Fund Management, LLC44,049New0.07%$1 MNov 16, 2026
84Allspring Global Investments Holdings, LLC38,715+1,515 (+4.07%)0.06%$1 MNov 4, 2026
85HSBC Holdings PLC37,792New0.06%$1 MNov 16, 2026
86Virtus Investment Advisers, LLC35,938-1,117 (-3.01%)0.06%$1 MNov 12, 2026
87Creative Planning33,670+5,349 (+18.89%)0.05%$0 MNov 2, 2026
88Susquehanna Fundamental Investments, LLC33,115+21,970 (+197.13%)0.05%$0 MNov 16, 2026
89Magnetar Financial LLC32,021New0.05%$0 MNov 13, 2026
90Commonwealth Equity Services, LLC30,677+2,103 (+7.36%)0.05%$0 MNov 2, 2026
91Vanguard Global Advisers, LLC30,430+15,346 (+101.74%)0.05%$0 MNov 13, 2026
92Campbell & CO Investment Adviser LLC27,207New0.04%$0 MNov 13, 2026
93Mitsubishi UFJ Asset Management Co., Ltd.26,424-220 (-0.83%)0.04%$0 MNov 5, 2026
94MetLife Investment Management, LLC26,0570 (0.00%)0.04%$0 MNov 16, 2026
95MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.25,892-552 (-2.09%)0.04%$0 MNov 16, 2026
96Truist Financial Corp25,0000 (0.00%)0.04%$0 MOct 30, 2026
97Bridgeway Capital Management, LLC24,585-415 (-1.66%)0.04%$0 MNov 16, 2026
98Empowered Funds, LLC24,585New0.04%$0 MNov 13, 2026
99Kera Capital Partners, Inc.24,0680 (0.00%)0.04%$0 MNov 13, 2026
100Russell Investments Group, Ltd.23,4590 (0.00%)0.04%$0 MNov 6, 2026

All 167 institutional investors, with who bought and sold →

Mutual funds holding 4D Molecular Therapeutics, Inc.#

146 funds hold shares worth $167 M (about 21.6% of the company). Since their previous reports 69 added shares and 43 sold, buying $25 M net.
Mutual funds holding 4D Molecular Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.1.61 M$21 M2.6%0.20%+22%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.59 M$21 M2.5%<0.01%−6.9%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.18 M$16 M1.9%0.02%+11%Jun 30, 2026
🇺🇸 Janus Henderson Global Life Sciences FundJanus Investment Fund788,444$10 M1.3%0.18%−6.6%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc.681,919$9 M1.1%0.10%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.460,479$6 M0.74%<0.01%+4.3%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.455,274$6 M0.73%0.06%newJun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors412,658$5 M0.66%0.04%+9.1%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC501,536$5 M0.80%0.01%+15%Jul 31, 2026
🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc.368,160$5 M0.59%0.10%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors329,017$4 M0.53%0.05%−2.9%Jun 30, 2026
🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC388,800$4 M0.62%0.10%−1.9%Jul 31, 2026
🇺🇸 State Street SPDR S&P Kensho New Economies Composite ETFSSGA Funds Management, Inc.275,621$4 M0.44%0.13%−11%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.226,579$2 M0.36%0.01%+14%May 31, 2026
🇺🇸 Federated Hermes MDT Small Cap Core FundFederated Hermes MDT Series209,243$2 M0.33%0.10%−56%Jul 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.158,931$2 M0.25%0.31%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors151,350$2 M0.24%0.13%+36%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC202,979$2 M0.32%<0.01%−13%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.183,926$2 M0.29%<0.01%−12%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP171,040$2 M0.27%0.01%+1.4%Jul 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.150,812$1 M0.24%0.08%+27%May 31, 2026
🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC150,059$1 M0.24%0.36%newMay 31, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC139,459$1 M0.22%0.03%−1.3%May 29, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP127,865$1 M0.20%0.02%+16%Jul 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.127,842$1 M0.20%<0.01%+21%May 31, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC126,274$1 M0.20%0.02%no changeMay 29, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP119,428$1 M0.19%<0.01%+3.9%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC86,878$1 M0.14%0.02%+28%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.111,444$1 M0.18%0.02%+15%Jul 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors82,924$1 M0.13%<0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust99,652$1 M0.16%0.04%+19%May 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC86,475$1 M0.14%0.03%−8.4%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC64,016$1 M0.10%0.04%+17%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC76,729$1 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.54,884$1 M0.09%0.02%no changeJun 30, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.53,185$1 M0.08%0.06%−6.7%Jun 30, 2026
🇺🇸 Bridge Builder Tax Managed Small/Mid Cap FundOLIVE STREET INVESTMENT ADVISERS LLC51,056$1 M0.08%0.02%no changeJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC50,241$1 M0.08%0.02%+12%Jun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC50,196$1 M0.08%0.01%newJun 30, 2026
🇺🇸 Voya Small Company PortfolioVoya Investments, LLC48,865$1 M0.08%0.30%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC60,927$1 M0.10%0.02%+21%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC59,387$1 M0.09%<0.01%−4.6%May 31, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC41,862$1 M0.07%0.05%no changeJun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC54,661$1 M0.09%0.11%−29%Jul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP44,264$0 M0.07%<0.01%+389%Jul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC33,010$0 M0.05%0.02%+1.0%Jun 30, 2026
🇺🇸 Voya MI Dynamic Small Cap FundVoya Investments, LLC43,888$0 M0.07%0.23%newMay 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP40,842$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Invesco BuyBack AchieversTM ETFInvesco Capital Management LLC39,203$0 M0.06%0.02%−5.5%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation28,200$0 M0.05%0.02%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.27,620$0 M0.04%<0.01%+11%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.35,199$0 M0.06%0.03%+20%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC25,000$0 M0.04%0.22%−50%Jun 30, 2026
🇺🇸 Allspring Disciplined Small Cap FundAllspring Funds Management, LLC24,814$0 M0.04%0.18%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC31,354$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.23,671$0 M0.04%0.02%+24%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC30,423$0 M0.05%<0.01%+3.4%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.22,589$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC19,724$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC18,530$0 M0.03%0.01%+1.8%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.24,050$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.17,132$0 M0.03%0.02%+17%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC21,908$0 M0.04%0.01%+15%Jul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC21,841$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC23,783$0 M0.04%0.12%—Apr 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.20,000$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.14,900$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP19,016$0 M0.03%<0.01%+231%Jul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC14,444$0 M0.02%0.02%+8.0%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC14,339$0 M0.02%0.02%no changeJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors13,953$0 M0.02%<0.01%−24%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC13,903$0 M0.02%0.02%+18%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company17,299$0 M0.03%0.01%no changeMay 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors12,505$0 M0.02%<0.01%−0.8%Jun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP15,939$0 M0.03%<0.01%+309%Jul 31, 2026
🇺🇸 Federated Hermes MDT Small Cap Core ETFFederated Advisory Services Company16,140$0 M0.03%0.06%−59%May 31, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation11,869$0 M0.02%0.07%−5.3%Jun 30, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC11,491$0 M0.02%0.03%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC14,789$0 M0.02%<0.01%+10%Jul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC10,108$0 M0.02%0.06%+28%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS9,952$0 M0.02%0.02%+19%Jun 30, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP13,010$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC9,707$0 M0.02%0.03%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC9,505$0 M0.02%0.02%+17%Jun 30, 2026
🇺🇸 Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value FundFederated Hermes Equity Funds8,085$0 M0.01%0.06%−92%Jun 30, 2026
🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC7,812$0 M0.01%0.03%−5.0%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC7,801$0 M0.01%0.01%no changeJun 30, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC7,665$0 M0.01%0.03%no changeJun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP9,930$0 M0.02%<0.01%+4.6%Jul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC7,558$0 M0.01%0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.7,200$0 M0.01%0.02%+19%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC7,081$0 M0.01%0.02%+9.2%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.7,011$0 M0.01%0.02%+37%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC6,032$0 M<0.01%0.02%+28%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC5,908$0 M<0.01%0.02%+16%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.5,842$0 M<0.01%0.02%−4.6%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION7,700$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC8,060$0 M0.01%0.04%—Mar 31, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP6,808$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP6,762$0 M0.01%<0.01%no changeJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at 4D Molecular Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$5.3 M
24 sales, 3 insiders
Net, 12 months
-$5.3 M
open market only
Insiders on file
16
since
-$12.0 M$0Dec 2023: bought $0 (0 trades), sold $580 K (2 trades)Dec 23Jan 2024: bought $0 (0 trades), sold $12.0 M (5 trades)Feb 2024: bought $0 (0 trades), sold $3.5 M (10 trades)Mar 2024: bought $0 (0 trades), sold $259 K (2 trades)MarApr 2024: bought $0 (0 trades), sold $304 K (2 trades)May 2024: bought $0 (0 trades), sold $45 K (2 trades)Jun 2024: bought $0 (0 trades), sold $340 K (2 trades)JunJul 2024: bought $0 (0 trades), sold $479 K (4 trades)Aug 2024: bought $0 (0 trades), sold $8 K (1 trades)Sep 2024: bought $0 (0 trades), sold $8 K (1 trades)SepSep 2025: bought $0 (0 trades), sold $19 K (1 trades)Oct 2025: bought $0 (0 trades), sold $73 K (3 trades)Nov 2025: bought $0 (0 trades), sold $17 K (1 trades)NovDec 2025: bought $0 (0 trades), sold $21 K (3 trades)Mar 2026: bought $0 (0 trades), sold $3 K (2 trades)Jun 2026: bought $0 (0 trades), sold $1.4 M (4 trades)JunJul 2026: bought $0 (0 trades), sold $738 K (3 trades)Aug 2026: bought $0 (0 trades), sold $1.5 M (6 trades)Sep 2026: bought $0 (0 trades), sold $841 K (3 trades)SepOct 2026: bought $0 (0 trades), sold $775 K (3 trades)
Bought (open market)Sold (open market)Hover a month for the totals
4D Molecular Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Scott BizilyChief Legal OfficerOption exercise10b5-1 plan+1,635$4.140$7 K10,252Form 4
filed Scott BizilyChief Legal OfficerSell10b5-1 plan-1,635$12.84$21 K8,617Form 4
filed David KirnSee Remarks, DirectorSell10b5-1 plan-58,061$12.92$750 K709,425Form 4
filed David KirnSee Remarks, DirectorSell10b5-1 plan-272$13.61$4 K709,153Form 4
filed Scott BizilyChief Legal OfficerOption exercise10b5-1 plan+1,635$4.140$7 K10,252Form 4
filed Scott BizilyChief Legal OfficerSell10b5-1 plan-1,635$13.65$22 K8,617Form 4
filed David KirnSee Remarks, DirectorSell10b5-1 plan-58,333$13.90$811 K767,486Form 4
filed Scott BizilyChief Legal OfficerOption exercise10b5-1 plan+584$6.490$4 K9,201Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: 4D Molecular Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
10.9 M
18.9% of shares · 10.43 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 20,715 shares at $12.14
  • : 6,973 shares at $12.56
  • : 17,035 shares at $15.00
  • : 50,000 shares at $14.68
  • : 6 shares at $14.18

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

4D Molecular Therapeutics, Inc. scorecard#

Passes 4 of the 12 checks that could be worked out: strongest in financial health (4 of 5), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.42 vs -2.98Diluted EPS -2.42 in fiscal 2025 against -2.98 the year before (report's currency).
    • ✗Net income higher than five years earlier-$140 M-$140 M in fiscal 2025 against -$57 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$140 MNet income -$140 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-187.2%-187.2% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-27.6%-27.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health4 of 5
    • ✓Short-term assets cover short-term liabilities9.4×Current ratio 9.39 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $60 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone4.49Z-score 4.49 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year7.4%Diluted shares up 7.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from 4D Molecular Therapeutics, Inc.'s statements, beside the median of Biotechnology.

4D Molecular Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-187.2%-60.5%
Net margin-164.4%-68.9%
Return on equity-27.6%-61.0%
Debt to equity0.00×0.26×
Free cash flow margin-128.7%-61.5%

3of 7on the Piotroski tests of financial strength

  • Net loss of $140 million, the 7th loss-making year in a row.
  • Free cash flow was negative: -$110 million.
  • The share count rose 7.4% in the year.
  • More cash than debt: net cash of $60 million.

4D Molecular Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

4D Molecular Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue850.0213.118147.0
Research and development1961419780615339
General and administrative49473633281714
Operating expenses245188134113897058
Operating income−160−188−113−110−71−57−51
Interest and finance income1927122.60.10.21.5
Other non-operating income (expense)1927122.50.0−0.01.5
Income tax000000—
Net income including minority interests−140−161−101−107−71−57−49
Net income attributable to shareholders−140−161−101−107−71−57−49
Earnings per share, basic-2.42-2.98-2.58-3.32-2.57-8.82-9.59
Earnings per share, diluted-2.42-2.98-2.58-3.32-2.57-8.82-9.59
Shares, weighted average (basic)5854393228——
Shares, weighted average (diluted)58543932286.45.1
Balance sheet
Cash and cash equivalents601492495215327750
Short-term investments34227639161950—
Receivables———00.01.51.0
Other current assets10108.47.08.54.41.9
Current assets41343529722125628353
Property, plant and equipment15202022145.15.0
Right-of-use (leased) assets18211213150—
Total assets56756034026235328858
Accounts payable114.43.53.34.81.81.7
Current liabilities44291916161713
Long-term debt0——————
Lease liabilities (non-current)16191213150—
Total liabilities61503231343228
Retained earnings−716−576−415−314−207−136−79
Shareholders' equity506511308231319256−73
Total liabilities and equity56756034026235328858
Shares outstanding5846433332275.2
Cash-flow statement
Depreciation and amortization4.74.74.22.41.51.41.0
Share-based compensation22262017145.03.5
Cash from operating activities−109−135−76−87−69−51−37
Capital expenditure−0.5−3.8−2.8−12−9.1−1.0−3.2
Cash from investing activities−93−302116−17−173−1.0−3.2
Shares issued———0114206—
Cash from financing activities1133371573.1118279−2.2
Change in cash−89−100197−101−124227−42
Report10-K10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What 4D Molecular Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Collaboration and License Revenue$85 M100%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where 4D Molecular Therapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

4D Molecular Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office$0 M0.3%
🇯🇵 Japan$85 M100%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at 4D Molecular Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.1 M
David Kirn
Other top executives, average
$2.7 M
the CEO earned 0.8× this
$100 invested is now
$34
4D Molecular Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025David Kirn$2.1 M$3.3 M$2.7 M$34
2024David Kirn$1.0 M−$6.8 M$779 K$25
2023David Kirn$10.3 M$15.4 M$4.3 M$91

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at 4D Molecular Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 5 · Material agreement 2 · New debt 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 12

4D Molecular Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Unregistered share sale8-K
Directors and officersResults announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officersBylaws or fiscal year changed8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Unregistered share sale8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of 4D Molecular Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2018$90 MNo. 3$50 to $250 million31equitySEC
Oct 2015$12 MNo. 2$10 to $50 million2equitySEC
Aug 2015$7 MNo. 1$2 to $10 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at 4D Molecular Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $160 K a year.

Certified, FY2025
1
#1,869 among companies on value.today
Worker positions
1
Median wage offered
$160 K
a year, full-time
Applications filed
1
4D Molecular Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Manager, ManufacturingArchitectural and Engineering Managers1$160 K

Where: Emeryville, CA 1

4D Molecular Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$160 K1
FY202433$135 K3
FY202311$130 K1
FY202211$115 K1
FY202144$95 K4

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as 4D Molecular Therapeutics, Inc.

Discuss 4D Molecular Therapeutics, Inc.#

3 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    4D Molecular Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $4 million (up 4500% from a year earlier) and a net loss of $78 million.

  • Insider trading in October 2026automatic update · Oct 31, 2026

    Directors and officers of 4D Molecular Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $774,931 in 3 trades. Awards, option exercises and shares withheld for tax are not counted.

  • Mutual funds: 146 funds hold $167 millionautomatic update · Jul 31, 2026

    146 mutual funds in 1 country hold shares of 4D Molecular Therapeutics, Inc. worth $167 million, about 21.6% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 69 funds added shares and 43 sold; on balance they bought $25 million. Share splits are not counted as trading.

How 4D Molecular Therapeutics, Inc. compares in Biotechnology

  • Market cap$637 M · higher than 61% of 726
  • Revenue$85 M · higher than 68% of 647
  • Net margin-208.6% · higher than 27% of 408
  • Price / sales6.6× · lower than 54% of 339
  • Price / book1.3× · lower than 73% of 534
  • FCF yield-17.2% · higher than 47% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
4D Molecular Therapeutics, Inc.🇺🇸$637 M—-208.6%—
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on September-2020
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at 4D Molecular Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show 4D Molecular Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about 4D Molecular Therapeutics, Inc.? Suggest a correction